Scott Sherriff commences his new role on July 3.
Scott Sherriff.
Auckland based medtech company, Aroa Biosurgery (AROA, ASX: ARX) is delighted to announce the appointment of seasoned executive Scott Sherriff as the company’s inaugural chief operating officer.
With more than 25 years’ experience in the pharmaceutical industry, Sherriff is a senior executive with extensive international experience. He has strong skills in leadership roles across sales and marketing and managing large cross-functional global teams.
Sherriff’s current role is chief commercial officer at Douglas Pharmaceuticals, which he has held since returning to New Zealand in 2015 after nearly 20 years working offshore.
Prior to his repatriation, Scott held senior roles at Bayer Pharma Ag and Novartis, and was highly adept at understanding consumers, differing markets, and navigating the complexities involved.
Aroa chief executive Brian Ward said: “We’re pleased that Scott is joining the Aroa leadership team in this key new role. With continued revenue growth and more than six million devices now applied to treating patients worldwide, we have many exciting opportunities ahead. Scott’s experience leading global strategy and operations will be assets during this next phase in Aroa’s journey.”
Sherriff will commence his new role at Aroa on July 3.
This is supplied content and not commissioned or paid for by NBR.
